INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2007

Xuezhikang, an extract of cholestin, reduced CHD events and all-cause mortality in type 2 diabetes patients with coronary heart disease.

In a subgroup analysis of the CCSPS, 591 diabetic patients with coronary heart disease were randomized to receive xuezhikang (n=306) or placebo (n=285) over an average follow-up of 4 years. CHD events occurred in 9.2% of the xuezhikang group versus 18.6% of the placebo group, reflecting a 50.8% risk reduction (P<0.001). Xuezhikang significantly lowered the risk of CHD death by 44.1% (6.9% vs. 12.3%, P<0.05) and all-cause death by 44.1% (27 vs. 45 deaths, P<0.01).

Study type
Randomized controlled trial (subgroup analysis)
Who was studied
591 patients with type 2 diabetes and coronary heart disease
What was measured
Coronary heart disease (CHD) events, CHD death, and all-cause mortality

THE PAPER

Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China coronary secondary prevention study (CCSPS).

Zhao SP, Lu ZL, Du BM, Chen Z, Wu YF, Yu XH, Zhao YC, Liu L, Ye HJ, Wu ZH, China Coronary Secondary Prevention Study (CCSPS). J Cardiovasc Pharmacol, 2007.

PubMed 17312447 ↗DOI 10.1097/fjc.0b013e31802d3a58 ↗

Heart & arteriesDiabetes & blood sugar

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.